The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the ...

Deregulation of the pRB/E2F pathway, which occurs frequently in human malignancy, is often associated with inappropriate proliferation and/or apoptosis. While the role of E2F1 in apoptosis induction ...

A Weill Cornell Medicine team has found that triple-negative breast cancer depends on the enzyme EZH2 to spread. By silencing key genes, EZH2 drives chaotic cell divisions and fuels metastasis.

As part of PRC2, EZH2 methylates histone 3 at lysine 27 (H3K27), which contributes to transcriptional silencing, thus promoting glycolysis and reducing the expression of MHC in the tumor. EZH2 is also ...

BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in ...

Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and helped explain how it promotes tumor growth. In this new study, the ...

National Institutes of Health (NIH) scientists and collaborators say they have discovered a new way in which RAS genes, commonly mutated in cancer, may drive tumor growth beyond their well-known role ...

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest to treat breast cancers, but a new study led by Weill Cornell Medicine suggests a way to stop it from spreading.

Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...